Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Degron Therapeutics Co.
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Columbia University
Theratechnologies
National Cancer Institute (NCI)
MacroGenics
Celgene
Zhujiang Hospital
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Rutgers, The State University of New Jersey
Mannkind Corporation